Addressing Early Talquetamab Toxicity Concerns
Panelists discuss how comprehensive patient education materials and manufacturer resources help patients prepare for and manage talquetamab adverse effects, with prior experience from chimeric antigen receptor (CAR) T-cell therapy providing valuable context for understanding potential complications such as cytokine release syndrome (CRS).
EP: 1.Alan's Multiple Myeloma Journey: Facing a New Diagnosis
EP: 2.Connecting With Multiple Myeloma Support Groups and Online Resources
EP: 3.Alan's Treatment Course and Quality-of-Life Goals
EP: 4.Coordinated Health Care Teams and Caregiver Support
EP: 5.Extending Talquetamab Education Beyond the Hospital
EP: 6.Addressing Early Talquetamab Toxicity Concerns
Patient education materials provided by the University of California, San Francisco included comprehensive handouts detailing expected adverse effects and mitigation strategies, supplemented by manufacturer-provided information packets about talquetamab. Alan Plisskin found these resources invaluable for understanding how to manage unfamiliar adverse effects, with specific product recommendations and practical management strategies. The combination of institutional and manufacturer materials created a comprehensive educational foundation for treatment preparation.
Plisskin’s previous experience with CRS during CAR T-cell therapy provided confidence in managing similar potential complications with talquetamab. The educational materials addressed serious adverse effects, including CRS and immune effector cell-associated neurotoxicity syndrome, though Plisskin’s prior experience reduced his anxiety about these possibilities. Support group webinars from organizations such as the International Myeloma Foundation and Multiple Myeloma Research Foundation supplemented formal medical education with peer experiences and current treatment information.
The comprehensive educational approach, combining written materials, prior treatment experience, and ongoing support group participation, exemplifies effective patient preparation for bispecific antibody therapy. The emphasis on providing information before treatment initiation allows patients to feel empowered and prepared for managing expected adverse effects. This proactive educational strategy contributes to improved patient confidence and treatment adherence throughout the therapy course.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
